Obesity
-
Randomized Controlled Trial
Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial.
The importance of lifestyle intervention for the prevention and treatment of type 2 diabetes (T2D) has been underscored by the limited benefit of pharmacologic therapies. We sought to determine whether genetic variants that contribute to T2D risk modify the response of weight and waist circumference to an intensive lifestyle intervention (ILI) in patients with obesity and T2D. Look AHEAD (Action for Health in Diabetes) is a randomized clinical trial comparing an ILI with a control condition on the risk of cardiovascular disease in overweight adults with T2D. ⋯ Nominally significant genotype-by-intervention interactions were detected for 1-year change in waist circumference with JAZF1, MTNR1B, and IRS1, and BMI with JAZF1. Highest GRS was associated with a greater reduction in waist circumference at year 1, although the variance in change attributable to the GRS was small. This study shows that the genetic burden associated with T2D risk does not undermine the effect of lifestyle intervention and suggests the existence of additional genomic regions, distinct from the T2D-susceptibility loci, which may enhance or mitigate weight loss.
-
Randomized Controlled Trial Multicenter Study
Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.
Look AHEAD (Action for Health in Diabetes) is a randomized trial determining whether intensive lifestyle intervention (ILI) aimed at long-term weight loss and increased physical fitness reduces cardiovascular morbidity and mortality in overweight and obese individuals with type 2 diabetes compared to control (diabetes support and education, DSE). We investigated the correlates of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker associated with heart failure (HF) risk, in a subsample from 15 of 16 participating centers and tested the hypothesis that ILI decreased NT-proBNP levels. Baseline and 1-year blood samples were assayed for NT-proBNP in a random sample of 1,500 without, and all 628 with, self-reported baseline CVD (cardiovascular disease) (N = 2,128). ⋯ DSE +14.2%, P = 0.046). The increased NT-proBNP associated with ILI was correlated with changes in HbA(1c), BMI, and body composition. In conclusion, among overweight and obese persons with diabetes, an ILI that reduced weight was associated with an increased NT-proBNP.
-
Randomized Controlled Trial
Relationship between the Bertin index to estimate visceral adipose tissue from dual-energy X-ray absorptiometry and cardiometabolic risk factors before and after weight loss.
The purpose of this study was to investigate the relationship between visceral adipose tissue (VAT), estimated with the Bertin index obtained from dual-energy X-ray absorptiometry (DXA), with cardiometabolic risk factors before and after a weight loss program and compare it with VAT measured with computed tomography (CT) scan. The study population for this analysis included 92 nondiabetic overweight and obese sedentary postmenopausal women (age: 58.1 ± 4.7 years, BMI: 31.8 ± 4.2 kg/m(2)) participating in a weight loss intervention that consisted of a caloric restricted diet with and without resistance training (RT). We measured (i) VAT using CT scan, (ii) body composition (using DXA) from which the Bertin index was calculated, (iii) cardiometabolic risk factors such as insulin sensitivity (using the hyperinsulinenic-euglycemic clamp technique), peak oxygen consumption, blood pressure, plasma lipids, C-reactive protein as well as fasting glucose and insulin. ⋯ Finally, results from the logistic regression analysis consistently showed that fat mass and lean body mass were independent predictors of pre- and post-VAT levels for both methods in our cohort. In conclusion, estimated visceral fat levels using the Bertin index may be able to trace variations of VAT after weight loss. This index also shows comparable relationships with cardiometabolic risk factors when compared to VAT measured using CT scan.
-
Randomized Controlled Trial Multicenter Study
The effect of tesofensine on appetite sensations.
Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed drugs. However, its long term effect on appetite in humans has not been studied. A multicentre phase II trial was divided into two parts (24 weeks each). ⋯ The reintroduction of TE in Part 2 increased CSS again (56 ± 17 mm at week 60), regardless of initial treatment/weight loss. We postulate that enhanced satiety is involved in early weight loss. Whether the attenuated effect on appetite seen after 24 weeks is due to a counteracting effect in the weight reduced state or whether the appetite suppressing effect of TE per se diminishes over time is, however, still unclear.
-
Randomized Controlled Trial
The individual and combined effects of glycemic index and protein on glycemic response, hunger, and energy intake.
Although high protein and low glycemic index (GI) foods are thought to promote satiety, little is known about the effects of GI, protein, and their interaction on hunger and energy intake several hours following a mixed meal. This study investigated the long term effects of GI, protein, and their combined effects on glucose, insulin, hunger, and energy intake in healthy, sedentary, overweight, and obese adults (BMI of 30.9 ± 3.7 kg/m(2)). Sixteen individuals participated separately in four testing sessions after an overnight fast. ⋯ The four meals had no differential effect on observed energy intake or self-reported hunger, satiety, and prospective energy intake. Low GI meals produced the smallest postprandial increases in glucose and insulin. There were no effects for GI, protein, or their interaction on appetite or energy intake 4 h after breakfast.